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Abstract
We have reviewed large studies that demonstrate different methods that have been adopted to prevent or delay the progression to 
Type 2 diabetes in high-risk individuals. The principal interventions include behavioural modifications in diet and physical activity, use 
of insulin sensitisers such as metformin and glitazones, and alpha-glucosidase inhibitors.
Although there is no evidence of benefit in health outcomes from large-scale population screening for impaired glucose tolerance 
(IGT) or impaired fasting glucose (IFG), screening of high-risk individuals has merit. During prolonged periods of dysglycaemia that 
precede diabetes, individuals remain largely asymptomatic. These periods can be from 8-10 years as extrapolated from the United 
Kingdom Prospective Diabetes Study data. This phase of pre-diabetes is not innocuous, and is often associated with the concurrent 
development of complications, which highlights the importance of early detection and treatment of this ‘silent killer’. Although different 
methods for screening of diabetes are available, preferred techniques include measurement of fasting plasma glucose and 2 hr 
post-load plasma glucose. People should be encouraged to eat correct diets, be active, and maintain a healthy weight - these 
behaviours have other benefits in addition to preventing or delaying the onset of Type 2 diabetes. There are various diagnostic criteria 
used for the diagnosis of diabetes. In this article we have presented two sets of criteria, one from the World Health Organization 
(WHO) and the other from the American Diabetes Association (ADA). 
 This article has been peer reviewed. Full text available at www.safpj.co.za SA Fam Pract 2008;50(4):14-20
Prevention
Diabetes is a worldwide pandemic associated with significant morbidity 
and mortality. The worldwide incidence of diabetes is projected to 
increase to 220 million by 2010 and 300 million by 2025.1 Early 
detection of those at risk for the development of diabetes and early 
intervention strategies can prevent the progression of diabetes and its 
associated complications. We need to develop materials that will help 
people understand their risks for pre-diabetes and what they can do 
to halt the progression to diabetes and even to “turn back the clock” if 
possible. 
Patients with high risk pre-diabetic conditions like IGT and IFG have 
about a 25%–50% lifetime risk of developing Type 2 diabetes and 
should be targeted for primary prevention.2 A number of well-designed 
intervention studies using lifestyle (diet and exercise) or drug therapy 
have been performed to this end. 
The Finnish Diabetes Prevention Study (FDPS)3 and the Chinese 
Da Qing Study5 have both conclusively shown that the development 
of Type 2 diabetes in people with pre-diabetes can be prevented by 
making changes in the diet to promote moderate weight loss, and 
by increasing their level of physical activity. The FDPS established 
a precedent for effectively altering lifestyle in patients with a high 
risk for diabetes. It studied 522 subjects with IGT using 1999 WHO 
criteria (FPG < 7.8 mmol/l; 2 hrs post glucose load 7.8-11.1 mmol/l). 
The intensive lifestyle modification group showed a 58% relative risk 
reduction as compared to controls, and continued effects were seen as 
a result of lifestyle change.3
The Da Qing study was undertaken in some 33 community clinics in 
Da Qing, China. A total of 577 subjects with IGT were randomised 
to a control group, diet control, exercise, or a combination of diet 
and exercise, and followed over 6 years. All the intervention groups 
showed a reduction in development of diabetes by 31% to 46% as 
compared with the control group.5 Guangwei Li, from the China-
Japan Friendship Hospital in Beijing, presented follow-up data in San 
Francisco at the 2008 ADA Conference, and concluded: “Group-based 
lifestyle interventions provided over 6 years can prevent or delay Type 
2 diabetes for up to 14 years after the active intervention. Whether 
lifestyle intervention also leads to a reduction in CVD events and 
mortality remains unclear.” 
A few other trials have been done using, in addition to behavioural 
modifications, pharmacological interventions, to delay the onset of 
diabetes, notably, the U.S based Diabetes Prevention Program (DPP),4 
the Troglitazone in Prevention of Diabetes Trial (TRIPOD),6 Diabetes 
Reduction Assessment with Ramipril and Rosiglitazone Medication 
(DREAM) trial,7 the STOP-NIDDM Trial8 and the Indian Diabetes 
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Prevention Programme (Indian DPP).20 More recently, results from the 
Actos Now for Prevention of Diabetes (ACT Now) trial were released at 
the ADA Congress (June 2008).9
The US-based DPP trial, with 3,234 subjects, focused on prevention 
of Type 2 diabetes in patients with IGT (2-hour post-glucose load of 
7.8–11.1 mmol/l) and/or IFG (FPG of 5.3–6.9 mmol/l). The patients 
were divided into 3 groups: 
• Intensive lifestyle intervention group 
• Standard lifestyle recommendations with metformin 850mg bd, and 
• Placebo group 
The study showed that 30-min/day of moderate physical activity 
(150-min per week), coupled with a 5–10% reduction in body weight, 
produced a 58% reduction in diabetes, whilst pharmacological 
intervention using metformin produced a 31% reduction in these 
high-risk patients. The secondary objectives of the study assessed 
differences between the three groups in the development of 
cardiovascular disease and its risk factors. Intensive lifestyle 
modification resulted in a decrease in cardiovascular risk factors.4             
The TRIPOD study was done to assess if chronic treatment of insulin 
resistance can preserve beta-cell function and prevent or delay 
the onset of Type 2 diabetes in high-risk patients. The efficacy of 
thiazolidinediones (TZD) in the treatment of diabetes was shown. 
This was due to the positive effect of TZDs on insulin sensitivity with 
reduction in hepatic glucose production, and increased peripheral 
utilisation of glucose, and preservation of pancreatic beta-cell function, 
The incidence of diabetes was 12,1% in the placebo group compared 
to 5,4% in the troglitazone group over 8 months. Troglitazone was 
removed from the market due to liver safety concerns in 2000.6
The DREAM study conducted using another thiazolidinedione, 
rosiglitazone, showed that in combination with lifestyle changes, it 
decreased progression from IGT to Type 2 diabetes by 60%. There 
were 14 cases of non-fatal heart failure in the rosiglitazone group and 
2 in the placebo group. However, there were no differences in mortality 
between the two groups. Treatment with ramipril did not lower the risk 
of diabetes but improved post-meal glucose profiles.7
In a study that randomised 1,429 subjects with IGT, the use of the 
alpha-glucosidase inhibitor acarbose in the STOP-NIDDM trial lowered 
post-prandial plasma glucose levels, reducing thereby the insulin 
demand and preserving beta-cell function. The primary endpoint of the 
study was the development of diabetes determined by an annual oral 
glucose tolerance test (OGTT).In this study the risk of patients with 
IGT developing diabetes was reduced by 25%, and the relative risk of 
cardiovascular events was reduced by 34%.8
In the Indian DPP, 531 subjects with IGT (WHO criteria) were 
randomised to four groups and followed for three years: 
• Control
• Lifestyle intervention
• Metformin (250 mg bd)
• Lifestyle and metformin (250 mg bd)
The relative risk reductions in the three intervention groups ranged 
from 26.4% to 28.5%. There were no significant differences between 
the three intervention groups.20
In the latest trial, using the thiazolidinedione pioglitazone, called 
the Actos Now for Prevention of Diabetes (ACT NOW) study, a 
combination of impaired glucose tolerance and impaired fasting 
glucose was present in 68% of patients, and the rest had isolated 
impaired glucose tolerance. Patients also had one or more other 
high-risk characteristics – at least one component of the metabolic 
syndrome, a family history of Type 2 diabetes, a history of gestational 
diabetes, the presence of polycystic ovary syndrome, or minority ethnic 
background. Patients were randomised to treatment with placebo or 
30 mg/day pioglitazone. If the drug was tolerated after one month, 
the dose was increased to 45 mg/day. Compared with 102 healthy 
matched controls, patients in the study showed a 48% reduction in 
insulin sensitivity and a 78% decrease in the insulin secretion/insulin 
resistance index. People with impaired glucose tolerance were 81% 
less likely to develop Type 2 diabetes over a 3-year period if treated 
with pioglitazone.9
Table I: Summary of clinical trials for the prevention of Type 2 diabetes
Study Therapy Relative Risk Reduction
Finnish Diabetes Prevention Study 














Diabetes Reduction Assessment 
with Ramipril and Rosiglitazone 
Medication (DREAM) 
Rosiglitazone + 
Diet + Exercise + 
Ramipril
60%
Study to Prevent Non-Insulin-
Dependent Diabetes Mellitus (STOP- 
NIDDM) trial
Acarbose 25%
Actos now (ACT NOW) for prevention 
of Diabetes Study Pioglitazone 81%
Indian DPP
Diet + Exercise
Metformin 250 mg bd
Diet, Exercise + 




There is much merit in identifying prediabetes and preventing its 
progression. The studies summarised in Table I establish the positive 
impact of lifestyle modifications on limiting progression. Currently, 
pharmacological intervention for IGT is not funded. Ideally, exceptions 
should be made for high-risk patients.
Screening
Three tests have been used to screen for diabetes: 
• Fasting plasma glucose (FPG)
• 2-hour post load plasma glucose and 
• Haemoglobin A1c
However, the ADA has recommended the FPG test for screening 
because it is easier and faster to perform, more convenient and 
acceptable to patients, and relatively inexpensive compared to 
other screening tests. The FPG test has more reproducible results 
than does the 2-hour post load plasma glucose test, has less intra-
individual variation, and has similar predictive value for development of 
microvascular complications of diabetes. 
The ADA defines diabetes as a FPG level of ≤ 7 mmol/L and 
recommends confirmation with a repeated screening test on a separate 
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day, especially for people with borderline results. The optimal screening 
interval is not known, but the ADA recommends a three year interval. 
Nearly 21% of people above the age of 60 years have diabetes. 
People with diabetes present with symptoms, but unfortunately most 
people with Type 2 diabetes live for years without realising that they 
have the disease. For some the disease becomes evident only after 
developing complications, such as cardiovascular disease, retinopathy, 
neuropathy that can lead to amputations, and nephropathy. Adults 
with diabetes have heart disease death rates about two to four times 
higher than adults without diabetes. Diabetes is the leading cause of 
new cases of blindness in adults 20-74 years of age, and is the leading 
cause of kidney failure. The rate of amputation for people with diabetes 
is 10 times higher than for people without diabetes. It therefore 
becomes important to detect the disease early.10
Screening recommendations 
There is no evidence of benefit in health outcomes from whole 
population screening for IGT, IFG or diabetes.21  However, screening 
of high-risk groups within a population has merit as potential diabetics 
may be discovered, and, with early treatment, complications may be 
prevented or reduced.
The National Institutes of Health (NIH) recommends that people of 
age ≥ 45 years consider getting tested for diabetes,11 and the ADA 
suggests a routine test every three years for those over 45 years, 
particularly if they are overweight, or for those under 45 years if they 
are overweight and have other diabetes risk factors.12 Those with 
additional diabetes risk factors may require more frequent testing. 
Screening for gestational diabetes mellitus should be reserved for use 
in women who meet one or more of the following criteria: 
•  25 years of age or older, obese (defined as more than 120% above 
their desirable body weight) 
• A family history of a first-degree relative with diabetes mellitus and 
• Belonging to a high-risk ethnic population.12
The recommendations for screening for diabetes in asymptomatic 
individuals are provided in Table II.
Table II: Recommendations for diabetes screening of asymptomatic persons13
Test at age 45 years; repeat every three years if the patient is 45 
years or older
Test before age 45 years; repeat more frequently than every three 
years if patient has one or more of the following risk factors:
• Obesity: ≥ 120% of desirable body weight or BMI ≥ 27 kg per m2 
• First-degree relative with diabetes mellitus 
•  Member of high risk-ethnic group (black, Hispanic, Native 
American, Asian) 
•  History of gestational diabetes mellitus or delivering a baby 
weighing more than 4,032 g  
• Hypertensive (≥ 140/90 mmHg) 
•  HDL cholesterol level < 0.90 mmol/L and/or triglyceride level 
≥ 2.83 mmol/L 
• History of IGT or IFG on prior testing
BMI = body mass index
HDL = high-density lipoprotein 
IGT = impaired glucose tolerance 
IFG = impaired fasting glucose
To date a few studies have been done in isolated populations to 
determine the prevalence of diabetes mellitus, impaired glucose 
tolerance (IGT) and impaired fasting glycaemia (IFG) in South 
Africa.15,16 Overall, these studies reveal a moderate prevalence 
of diabetes and high prevalence of total disorders of glycaemia 
suggesting that this community is well into the epidemic of glucose 
intolerance. The prevalence rate of diabetes in South African Indians is 
higher than in other population groups (See Table III).22
Table III22: Prevalence rate of diabetes per population group and gender
Populations group Males % Females % Total %
Urban black African   5.4   7.3   6.4
Non-urban black 
African   5.4   8.4   7.4
Coloured   5.1   7.3   6.2
White   5.1   7.3   6.2
Asian/Indian 18.0 16.4 17.1
South Africa   4.7   6.2   5.5
Haemoglobin A1c is currently not recommended for the diagnosis of 
diabetes, based upon expert consensus.25 This is because HbA1C is 
difficult to standardise between laboratories and lacks the sensitivity 
to distinguish IGT from diabetes.23 It is, however, the most widely 
accepted laboratory test for the measurement of glycaemic control, and 
is recommended for routine use in the management of patients with 
diabetes.
Diagnosis
Diagnosis of diabetes defines a group of patients at a high risk for 
developing micro- and macrovascular disease. For individuals with 
symptoms of diabetes, such as polyuria, polydipsia or unexplained 
weight loss only elevated FPG ≥ 7.0 mmol/l or elevated random 
plasma glucose ≥ 11 mmol/l is required to confirm the diagnosis. The 
diagnostic criteria and classification recommendations have been 
established by the WHO (1980), and so too by the ADA (1997) and 
(2003), who use more stringent criteria.
In order to make a diagnosis of diabetes it becomes necessary to 
establish hyperglycaemia. The plasma glucose must be measured by 
a laboratory method. The presence of diabetes symptoms with a single 
random venous plasma glucose value ≥ 11.1 mmol/L, or elevated 
fasting venous plasma glucose of ≥ 7.0 mmol/l are diagnostic of 
diabetes.23 In the absence of unequivocal hyperglycaemia with acute 
metabolic decompensation, these criteria should be confirmed by 
repeat testing on a different day. 
An oral glucose tolerance test (OGTT) is not normally needed in 
routine clinical practice, but as many as 30% of people with diabetes 
will not be diagnosed if only fasting measurements are done. An OGTT 
to establish diagnostic status need only be considered if blood glucose 
values lie in the uncertain range (i.e. between the levels that establish 
or exclude diabetes) and fasting blood glucose levels are below those, 
which establish the diagnosis of diabetes. If an OGTT is performed, it 
is sufficient to measure the blood glucose values while fasting and at 
2-hours after a 75 gm oral glucose load. For children the oral glucose 
load is related to body weight: 1.75 g glucose per kg. The diagnostic 
criteria in children are the same as for adults.18,19 
Diagnostic interpretations of the fasting and 2 hr post-load 
concentrations in non-pregnant subjects are shown in Table IV and V 
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below. It must be pointed out that there are different criteria adopted by 
different national and international groups for the diagnosis of diabetes. 
We present here diagnostic criteria used by the two large international 
groups – the ADA and the WHO.23 Local South African guidelines use 
the same values as the ADA.24
Table IV: WHO criteria for diabetes and impaired glucose tolerance23
Glucose concentration in mmol/l
Plasma Whole blood
Venous Capillary Venous Capillary
Diabetes Mellitus
Fasting value ≥ 7.8 ≥ 7.8 ≥ 6.7 ≥ 6.7
Or
2 hr after 75 gm 
glucose load ≥ 11.1 ≥ 12.2 ≥ 10.0 ≥ 11.1
Impaired Glucose 
Tolerance
Fasting value < 7.8 < 7.8 < 6.7 < 6.7
2 hr after 75 gm 
glucose load 7.8 – 11.0 8.9 – 12.1 6.7 – 9.9 7.8 – 11.0
In June 1997, the ADA announced new recommendations for the 
diagnosis of diabetes,23 and in 2003 these guidelines were updated 
with modifications regarding the diagnosis of IFG. The new guidelines 
also lowered the cut-off values for fasting glucose concentrations used 
to diagnose diabetes.25
Table V: ADA diagnostic criteria, 199723
1   Symptoms + random plasma glucose ≥ 11.1 mmol/l
2   Fasting plasma glucose ≥ 7.0 mmol/l
3   75 gm OGTT 2 hr plasma glucose ≥ 11.1 mmol/l
• Each method confirmed on a subsequent day by any method
• Impaired fasting glucose (IFG) ≥ 6.1 and < 7.0 mmol/l
Glucose tolerance is classified into three categories based on the FPG:
• Normal: FPG < 5.6 mmol/l 
• IFG: FPG ≥ 5.6 mmol/l  but <7.0 mmol/l 
• Diabetes: FPG ≥ 7.0 mmol/l 
IFG is comparable to IGT, which is defined as plasma glucose levels 
between 7.8 and 11.1 mmol/l 2-hr after a 75 g OGTT. Individuals with 
IFG or IGT are at substantial risk for developing Type 2 diabetes (a 
40% risk over the next five years) and cardiovascular disease. 
FPG is the preferred screening test for children and non-pregnant 
adults, whereas OGTT is the recommended test for Gestational 
Diabetes Mellitus (GDM), although the diagnostic levels for GDM are 
different than for others (See Table VI).27,28
Table VI: Diagnosis of GDM with a 100 g or 75 g glucose load27,28
mmol/l









Two or more of the venous plasma concentrations must be met or 
exceeded for a positive diagnosis of GDM. The test should be done 
in the morning after an overnight fast of between 8 and 14 hr and 
after at least 3 days of unrestricted diet (≥ 150 g carbohydrate/day) 
and unlimited physical activity. The subject should remain seated and 
should not smoke throughout the test.
Diabetes mellitus is clinically and genetically a heterogeneous 
disorder due either to insulin deficiency or to resistance to the action 
of insulin. Research has led to the recognition that the different types 
of diabetes have different causes although their pathology after onset 
of diabetes may be similar. The classification of this heterogeneous 
group of disorders is summarised in Table VII below. The WHO Expert 
Committee on Diabetes recommends this classification.18,19
Table VII highlights the different clinical presentations and genetic and 
environmental aetiologic factors that distinguish the types of diabetes. 
Table VII: Classification of the types of diabetes class name characteristics17,18,19
Type 1
•  Low or absent levels of circulating 
endogenous insulin 
•  Onset predominantly in youth but can 
occur at any age
•  Associated with certain HLA and GAD 
antigens
•  Abnormal immune response and islet 
cell antibodies are frequently present at 
diagnosis
•  Aetiology probably only partially genetic, 
as only ~35% of monozygotic twins 
are concordant for insulin dependent 
diabetes
Type 2
•  Insulin levels may be normal, elevated, 
or depressed
•  Hyperinsulinaemia and insulin 
resistance in most patients
•  Insulinopaenia develops as beta-cell 
function declines
•  Not insulin-dependent or ketosis-prone 
under normal circumstances, but may 
use insulin as disease progresses
•  Onset predominantly after age 40 years 
but can occur at any age
•  Approximately 50% of men and 70% of 
women are obese
•  Aetiology probably strongly genetic as 
60%-90% of monozygotic twins are 
concordant for non-insulin dependent 
diabetes
Gestational diabetes (GDM)
•  Glucose intolerance that has its onset or 
recognition during pregnancy
•  Associated with older age, obesity, 
family history of diabetes
•  Conveys increased risk for the woman 
for subsequent progression to non-
insulin dependent diabetes mellitus 
(NIDDM)
•  Associated with increased risk of 
macrosomia
Other types of diabetes
• Pancreatic disease
• Hormonal disease
•  Causes of hyperglycaemia are known 
for some conditions e.g. pancreatic 
disease
• Drug or chemical exposure
• Insulin receptor abnormalities
• Certain genetic syndromes
Conclusion
Although typically Type 2 diabetes presents at about the age of 40 
years, there are recent trends for the disease to present at earlier 
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ages, in particular related to increasing obesity and lack of regular 
exercises or physical activity. It has become imperative to implement 
lifestyle modifications most aggressively if we are to stem the 
increasing incidence of Type 2 diabetes. It requires an ownership of the 
responsibility to achieve this. Not only is it an initiative in which individual 
patients and their care providers have to be involved, but also parents, 
schools, medical aid funders, Departments of Health and Government. 
Regular physical training must be reintroduced at all grades in the 
school. Perhaps then our fight against diabetes will begin.  
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